Search results
Results from the WOW.Com Content Network
The Montreal Cognitive Assessment (MoCA) is a widely used screening assessment for detecting cognitive impairment. [1] It was created in 1996 by Ziad Nasreddine in Montreal , Quebec . It was validated in the setting of mild cognitive impairment (MCI), and has subsequently been adopted in numerous other clinical settings.
Previously, diagnosis was done from observation of hypopigmentation which is obvious at birth, but this is now insufficient early on to distinguish between the seven major types of OCA. [ 2 ] Prenatal testing has been achieved through fetal skin biopsy followed by subsequent histologic and electron microscope examination for melanin levels. [ 12 ]
The main discussion of these abbreviations in the context of drug prescriptions and other medical prescriptions is at List of abbreviations used in medical prescriptions. Some of these abbreviations are best not used, as marked and explained here.
Pronunciation follows convention outside the medical field, in which acronyms are generally pronounced as if they were a word (JAMA, SIDS), initialisms are generally pronounced as individual letters (DNA, SSRI), and abbreviations generally use the expansion (soln. = "solution", sup. = "superior").
Cognitive impairment is an inclusive term to describe any characteristic that acts as a barrier to the cognition process or different areas of cognition. [1] Cognition, also known as cognitive function, refers to the mental processes of how a person gains knowledge, uses existing knowledge, and understands things that are happening around them using their thoughts and senses. [2]
Interlocking pentagons used for the last question. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills.
Sortable table Abbreviation Meaning o: Nothing [ō—letter o with overbar] O 2: oxygen: OA: osteoarthritis: OAB: Overactive bladder: OAF: osteoclast activating factor
The prevalence of OCA type 2 is estimated at 1/38,000-1/40,000 in most populations throughout the world, with a higher prevalence in the African population of 1/3,900–1/1,500. [7] Other diseases associated with the deletion of the OCA2 gene are Angelman syndrome (light-colored hair and fair skin) and Prader–Willi syndrome (unusually light ...